Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
1.250
+0.100 (8.70%)
At close: Nov 6, 2026, 4:00 PM EST
1.250
0.00 (0.00%)
Pre-market: Nov 9, 2026, 4:00 AM EST
Cellectar Biosciences Employees
Cellectar Biosciences had 11 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Cellectar Biosciences the 39,956th largest employer in the world and 5,961st in the United States.
Employees
11
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,029,427
Market Cap
11.82M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 11 | 0 | - |
| Dec 31, 2024 | 11 | -9 | -45.00% |
| Dec 31, 2023 | 20 | 5 | 33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Fractyl Health | 100 |
| Daré Bioscience | 24 |
| Passage Bio | 24 |
| BioCardia | 21 |
| Radiopharm Theranostics | 14 |
| Lipocine | 14 |
| Psyence Biomedical | 12 |
CLRB News
- 4 days ago - Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 6 days ago - Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 - GlobeNewsWire
- 12 days ago - Cellectar’s iopofosine case study shows complete response over 8 years - TheFly
- 13 days ago - Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131 - GlobeNewsWire
- 24 days ago - Cellectar Biosciences presents efficacy data from CLOVER WaM trial - TheFly
- 25 days ago - Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia - GlobeNewsWire
- 5 weeks ago - Cellectar Biosciences Slides: Corporate presentation - Filings
- 5 weeks ago - Cellectar Biosciences to present data from Phase 2 CLOVER WaM trial - TheFly